A Chinese pharmaceutical and health technology company headquartered in Beijing’s Changping district has been formally designated as the anchor entity for Beijing’s first brain-science and brain-computer interface incubation platform under a specific municipal future-industry programme. Beijing Changfazhan Pharmaceutical and Health Technology Co., Ltd. was named in a Beijing Municipal Bureau of Economy and Information Technology (Beijing MIIT) announcement dated 1 July 2026 (English release 7 July via english.beijing.gov.cn) as the applicant behind the Changfazhan Brain Science and Brain-Computer Interface Incubation Platform (Chinese: 昌发展脑科学与脑机接口育新平台). The platform is one of seven newly recognised Future Industry Incubation Platforms in a third batch that brings Beijing’s total across three batches to 27 platforms.

The BCI designation is worth reading precisely. It is the first BCI-specific platform under Beijing’s Future Industry Incubation Platform programme (Chinese: 未来产业育新平台), which is a specific Beijing MIIT initiative to identify and support named anchor entities for emerging industrial categories. It is NOT the first Beijing recognition of BCI as a strategic industry. Zhongguancun Changping had already established a Brain Science and BCI Industrial Park during 2025, and Zhongguancun Haidian released plans for a BCI Industrial Cluster on 27 March 2026 at the Zhongguancun Forum’s Brain-Computer Interface Innovation Development Forum session, where Haidian District deputy head Lin Hang stated that the district is already home to 27 core BCI companies. Both prior Zhongguancun bodies are formally different programme types (Chinese: 产业集聚区 industrial cluster / 产业园 industrial park). The 育新平台 programme is a distinct incubation-anchor designation, and the Changfazhan platform is the first BCI-scoped entry under that specific mechanism.

The Beijing Future Industry Incubation Platform batch three specifics

The Beijing MIIT third batch names seven platforms across three broad Beijing future-industry categories (information, health, manufacturing) and six specific fields. The six fields are artificial general intelligence, atom-level manufacturing, brain science and brain-computer interfaces, quantum information, metaverse, and smart mobility. Per the Beijing MIIT announcement, this is the first time Beijing has recognised incubation platforms specifically for smart mobility, atom-level manufacturing, and brain science with BCIs under this programme.

The seven newly recognised platforms are distributed across six districts: the Beijing Economic-Technological Development Area (two platforms), Haidian, Changping, Huairou, Shunyi, and Shijingshan. Three of the seven are named in the English release: MIRACLEPLUS Artificial General Intelligence Incubation Platform in Haidian, Gaosite Smart Mobility Incubation Platform in Shunyi, and the Huairou Incubation Platform for Atom-Level Manufacturing. The Changfazhan BCI platform in Changping is named in the underlying Chinese Beijing MIIT release and the accompanying PDF list of all seven; the specific validity period assigned to each platform is three years.

The aggregate numbers Beijing MIIT reports across all 27 platforms are 1,000-plus enterprises attracted, 216 designated as specialised, high-end, or innovation-driven, 47 national-level “Little Giant” enterprises, and 10 “Win the Future” award recipients. All 27 platforms are located across 12 Beijing districts.

Where the Beijing move fits in the broader China industrial-builder cadence

Beijing’s Changfazhan platform designation continues a specific eight-week cascade of Chinese BCI industrial-policy moves that Inside BCI has been tracking through separate coverage. Shanghai issued the earliest municipal BCI action plan on 10 January 2025. The seven-ministry Implementation Opinions on Promoting the Innovative Development of the BCI Industry (work.miit.gov.cn document 工信部联科〔2025〕164号) issued on 23 July 2025 became the national anchor. Jiangsu issued its provincial BCI Action Plan on 10 March 2026. Guangdong issued its BCI Science-Technology and Industry Coordinated Development Action Plan for 2026-2030 on 24 June 2026. The Guangdong-Hong Kong-Macao Greater Bay Area BCI Industry Innovation Alliance was established in Guangzhou on 2 July 2026 with 124 founding members. Beijing’s Changfazhan platform designation on 1 July 2026 makes the capital the latest municipal actor to name a specific BCI anchor entity under its own future-industry programme, alongside the two earlier Zhongguancun BCI bodies (Changping’s Brain Science and BCI Industrial Park established during 2025 and Haidian’s BCI Industrial Cluster plans released on 27 March 2026) that operate under different programmes.

Shanghai municipal science commission director’s H1 2026 financing claim

Separately, on 6 July 2026, the English wire service of China News Service (ecns.cn, byline Zhang Dongfang, editor Mo Honge) reported that Luo Dajin, the director of the Shanghai Municipal Science and Technology Commission (Chinese: 上海市科学技术委员会, romanised STCSM), made three specific claims about Shanghai’s share of Chinese BCI activity in the first half of 2026. Luo Dajin’s Chinese name is 骆大进; he has served as STCSM director since February 2023, per the STCSM leadership page. His statement, as reported by ECNS in one paragraph, was that in H1 2026 Shanghai hosted nearly 60 per cent of China’s BCI financing events, accounted for nearly 40 per cent of the disclosed BCI funding amount, and houses one-third of the country’s BCI companies. The ECNS report does not identify the forum or occasion at which Luo Dajin made the statement, and does not disclose the specific denominator or numerator behind the three percentages. ECNS also does not define what specifically counts as a “BCI financing event.”

The three figures deserve to be read as three distinct claims, not one aggregate figure. A 60 per cent share of financing events (event count) and a 40 per cent share of disclosed funding amount (yuan value) together imply that the average Shanghai BCI financing event is smaller in yuan terms than the average non-Shanghai Chinese BCI financing event. A one-third share of Chinese BCI companies (headcount) combined with a 60 per cent share of financing events implies that Shanghai-based BCI companies are raising capital roughly three times as often as non-Shanghai Chinese BCI companies on a per-company basis. Those are the specific structural claims that Luo Dajin’s H1 2026 numbers make about Shanghai’s position.

Luo Dajin also stated, per ECNS, that Shanghai has expanded its list of strategic frontier fields to 20, houses half of China’s neutral-atom quantum computer manufacturers, and has established four municipal-level future industry clusters plus two future industry cultivation zones. ECNS does not name the four clusters or the two cultivation zones. Inside BCI’s Gestala coverage on 3 July 2026 identified the Minhang District Brain Intelligence World (Chinese: 脑智天地) as a specific Shanghai BCI cluster where Gestala opened its NeuroAI headquarters, but ECNS’s report of Luo Dajin’s statement does not itself name that cluster as one of the four. No independent second-source corroboration of the H1 2026 percentages has been located as of publication. The claim is an on-record municipal official statement, not an independently audited market share.

Where the two capital-city moves sit strategically

The specific combination of Beijing designating a first Changping-based BCI incubation platform under the Future Industry programme and Shanghai’s science commission director claiming Shanghai is capturing the majority of Chinese BCI financing on a per-event basis is the strategic pattern of the week. Both moves fit the Industrial Builder posture that Inside BCI has identified across four global BCI regulatory postures: the state-patchwork United States (Colorado, California, Montana, Connecticut enacted); the horizontal-regulator European Union (AI Act plus GDPR); the rights-first Chile (constitutional neurorights); and the industrial-builder China with South Korea. Neither the Beijing designation nor the Shanghai claim requires new consent frameworks or restricts BCI development. Both are positive-industrial-policy actions to attract enterprises, capital, and talent to specific municipal or provincial jurisdictions.

The Shanghai-Beijing framing has a specific implication for the Chinese BCI cohort’s geographic distribution. Shanghai’s cluster gravity has been visibly documented across Inside BCI’s coverage of Gestala (Minhang, 3 July 2026), Neuracle’s STAR Market IPO prospectus (Shanghai, 22 June 2026), and adjacent moves. Beijing’s Changping designation names a specific pharmaceutical and health-technology anchor entity rather than an already-visible BCI operator, which is a different structural approach to attracting BCI capital than Shanghai’s cluster-of-existing-operators posture. Whether the Changping platform actually attracts operator-stage BCI companies away from Shanghai’s cluster gravity, or serves as an early-stage incubation anchor complementary to it, is the specific commercial question the platform designation opens.

What to watch

The first signal is which specific BCI companies are named as tenants or portfolio companies of the Changfazhan Brain Science and BCI Incubation Platform. Beijing MIIT has not yet disclosed the tenant list. The identity of the first two to three anchor tenants will indicate whether the Changping platform attracts Chinese-market-focused BCI companies or serves as a landing point for BCI companies with international ambition seeking Beijing regulatory proximity.

The second signal is any specific yuan-denominated funding commitment tied to the Changfazhan platform. The Beijing MIIT announcement does not specify a funding amount. Any subsequent Changping district or Beijing MIIT disclosure of a specific yuan commitment will be the signal about the platform’s actual capital deployment scale.

The third signal is whether other Chinese municipalities move to designate BCI-specific platforms under their own equivalent programmes. Shanghai’s future-industry cluster framework and Shenzhen’s parallel structure both have programmes that could be extended to specifically-named BCI platforms. Whether such designations follow in the coming quarters will indicate the pace of municipal-level BCI industrial policy following the national July 2025 seven-ministry Implementation Opinions.

The fourth signal is whether the H1 2026 Shanghai financing figures Luo Dajin cited can be independently verified against private-market data providers. 36Kr, Investment Circle, and other Chinese venture-market trackers publish quarterly Chinese BCI financing summaries. Whether their tallies confirm or contradict the 60 per cent events / 40 per cent amount / one-third companies triad will indicate whether Luo Dajin’s statement is a municipal-positioning claim or an independently verifiable market share.

Sources

• Seven More! Beijing Now Has 27 Incubation Platforms for Future Industries (english.beijing.gov.cn, English release 7 July 2026, underlying Beijing MIIT announcement dated 1 July 2026)
• Beijing MIIT primary Chinese announcement, 1 July 2026
• Beijing MIIT PDF list of seven platforms in the third batch
• Shanghai accounts for nearly 60% of China’s BCI financing events in H1, official says (Ecns.cn, 6 July 2026, byline Zhang Dongfang, editor Mo Honge)
• Shanghai Municipal Science and Technology Commission (STCSM) leadership page (Luo Dajin director since February 2023)
• Inside BCI: Guangdong BCI Action Plan Dual-Core, 26 June 2026 · Three BCI industrial policy launches China South Korea eight weeks, 21 June 2026 · Neuracle STAR Market IPO prospectus accepted, 22 June 2026 · Gestala ultrasound BCI Angel+ Shanghai HQ, 3 July 2026 · NMPA Announcement 24 BCI classification, 4 July 2026